EA201391591A1 - Лечение множественной миеломы - Google Patents

Лечение множественной миеломы

Info

Publication number
EA201391591A1
EA201391591A1 EA201391591A EA201391591A EA201391591A1 EA 201391591 A1 EA201391591 A1 EA 201391591A1 EA 201391591 A EA201391591 A EA 201391591A EA 201391591 A EA201391591 A EA 201391591A EA 201391591 A1 EA201391591 A1 EA 201391591A1
Authority
EA
Eurasian Patent Office
Prior art keywords
multiple myeloma
treatment
subject
phenotype
proliferation
Prior art date
Application number
EA201391591A
Other languages
English (en)
Inventor
Кристофер Джон Бёрнс
Эндрю Спенсер
Кэтрин Энн Монахен
Original Assignee
Им Байосайенсиз Аустралиа Пти Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47107683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201391591(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Им Байосайенсиз Аустралиа Пти Лтд. filed Critical Им Байосайенсиз Аустралиа Пти Лтд.
Publication of EA201391591A1 publication Critical patent/EA201391591A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Предложен способ лечения субъекта, страдающего множественной миеломой на стадии, характеризуемой повышением распространения клеток ММ, которые (1) не реагируют на IL-6 и/или (2) имеют фенотип CD45-, включающий введение субъекту некоторого количества соединения формулы Ib
EA201391591A 2011-05-02 2012-05-01 Лечение множественной миеломы EA201391591A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481425P 2011-05-02 2011-05-02
PCT/AU2012/000462 WO2012149602A1 (en) 2011-05-02 2012-05-01 Multiple myeloma treatment

Publications (1)

Publication Number Publication Date
EA201391591A1 true EA201391591A1 (ru) 2014-12-30

Family

ID=47107683

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391591A EA201391591A1 (ru) 2011-05-02 2012-05-01 Лечение множественной миеломы

Country Status (20)

Country Link
US (1) US20140171433A1 (ru)
EP (1) EP2704722A4 (ru)
JP (1) JP2014514337A (ru)
KR (1) KR20140081757A (ru)
CN (1) CN103533939A (ru)
AP (1) AP2013007281A0 (ru)
AU (1) AU2012250491A1 (ru)
BR (1) BR112013028420A2 (ru)
CA (1) CA2834414A1 (ru)
CL (1) CL2013003143A1 (ru)
CO (1) CO6900134A2 (ru)
EA (1) EA201391591A1 (ru)
IL (1) IL228981A0 (ru)
MA (1) MA35129B1 (ru)
MD (1) MD20130089A2 (ru)
MX (1) MX2013012785A (ru)
PE (1) PE20140750A1 (ru)
SG (1) SG194212A1 (ru)
WO (1) WO2012149602A1 (ru)
ZA (1) ZA201308918B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104030990B (zh) 2007-03-12 2017-01-04 Ym生物科学澳大利亚私人有限公司 苯基氨基嘧啶化合物及其用途
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
WO2015184087A2 (en) 2014-05-28 2015-12-03 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
TWI729644B (zh) * 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
AU2015292678B2 (en) 2014-07-22 2020-10-22 Cb Therapeutics, Inc. Anti-PD-1 antibodies
CA2956399A1 (en) 2014-08-05 2016-02-11 Cb Therapeutics, Inc. Anti-pd-l1 antibodies
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
CN105837515B (zh) * 2016-04-06 2018-08-03 中国药科大学 一种JAK抑制剂Momelotinib的制备方法
CN106075046A (zh) * 2016-07-31 2016-11-09 孙书芳 一种治疗肝肾阴虚型多发性骨髓瘤的中药
US10487321B2 (en) * 2016-09-29 2019-11-26 PZM Diagnostics, LLC Method of extraction of genomic DNA for molecular diagnostics and application
US20200209247A1 (en) * 2017-09-15 2020-07-02 University Of Iowa Research Foundation Methods for identifying myeloma tumor-initiating cells and targeted therapy
CN109045040A (zh) * 2018-03-12 2018-12-21 首都医科大学附属北京天坛医院 Cyt387用于制备治疗神经胶质瘤的药物的应用
CN111100076A (zh) * 2019-12-30 2020-05-05 武汉九州钰民医药科技有限公司 Jak抑制剂莫美洛替尼的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080267905A1 (en) * 2004-05-05 2008-10-30 Celgene Corporation Methods and Compositions Using Selective Cytokine Inhibitory Drugs for Treatment and Management of Cancers and Other Diseases
MX2009005649A (es) * 2006-11-27 2009-06-08 Ares Trading Sa Tratamiento para mieloma multiple.
CN104030990B (zh) * 2007-03-12 2017-01-04 Ym生物科学澳大利亚私人有限公司 苯基氨基嘧啶化合物及其用途

Also Published As

Publication number Publication date
IL228981A0 (en) 2013-12-31
CA2834414A1 (en) 2012-11-08
ZA201308918B (en) 2014-08-27
BR112013028420A2 (pt) 2017-01-24
AP2013007281A0 (en) 2013-11-30
MX2013012785A (es) 2014-05-28
AU2012250491A1 (en) 2013-05-02
EP2704722A1 (en) 2014-03-12
WO2012149602A1 (en) 2012-11-08
KR20140081757A (ko) 2014-07-01
EP2704722A4 (en) 2014-11-05
MD20130089A2 (ru) 2014-05-31
SG194212A1 (en) 2013-11-29
PE20140750A1 (es) 2014-07-06
MA35129B1 (fr) 2014-05-02
CN103533939A (zh) 2014-01-22
CO6900134A2 (es) 2014-03-20
JP2014514337A (ja) 2014-06-19
CL2013003143A1 (es) 2014-07-04
US20140171433A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
EA201391591A1 (ru) Лечение множественной миеломы
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201591610A1 (ru) Ингибиторы кинуренинового пути
EA201591327A1 (ru) Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
EA201490814A1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
ATE533489T1 (de) Behandlung von multiplem myelom
EA201490696A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh
EA201690989A1 (ru) Ингибиторы syk
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201591745A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
BR112015022197A2 (pt) tratamento de cataplexia
EA201290677A1 (ru) Соединения обратного амида в качестве ингибиторов протеиндеацетилазы и способы их применения
MX343561B (es) Compuestos de imidazolpiridazina.
EA201201030A1 (ru) 5-алкинилпиримидины
EA201400735A1 (ru) Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
EA201291357A1 (ru) Способы лечения с применением ингибиторов tlr7 и/или tlr9
EA024702B8 (ru) Новые иммуномодуляторные и противовоспалительные соединения
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
EA201491747A1 (ru) Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов
EA201490614A1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-kB
MX2014000515A (es) Metodo de tratamiento de inflamacion e himpertencion secuestrante de gama -cetoaldehido.
EA201491500A1 (ru) Способы лечения фиброза